Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011454 | 0.85 | GRM5 (0.74) | GRM5ALDH1A1NPC1TP53POLB | |
| SCHEMBL2009595 | 0.78 | GRM5 (1.00) | GRM5 | |
| SCHEMBL6860400 | 0.77 | GRM5 (0.62) | GRM5ALDH1A1NPC1TP53POLB | |
| SCHEMBL30795678 | 0.77 | GRM5 (0.62) | GRM5ALDH1A1NPC1TP53POLB | |
| SCHEMBL2009600 | 0.76 | GRM5 (1.00) | GRM5 | |
| SCHEMBL12938248 | 0.75 | GRM5 (0.59) | GRM5ALDH1A1NPC1TP53POLB | |
| SCHEMBL12938243 | 0.73 | GRM5 (0.57) | GRM5ALDH1A1NPC1TP53POLB | |
| SCHEMBL12965399 | 0.73 | GRM5 (0.57) | GRM5ALDH1A1NPC1TP53POLB | |
| SCHEMBL2014092 | 0.72 | GRM5 (0.70) | GRM5 | |
| SCHEMBL4325876 | 0.71 | GRM5 (1.00) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513118-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | claimed |
| EP-2513118-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | claimed |
| US-20120252800-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-04 | — | — | US | claimed |
| WO-2011073347-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-9174953-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-03 | — | — | US | disclosed |
| US-9174953-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-03 | — | — | US | disclosed |
| US-9174953-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-03 | — | — | US | disclosed |
| EP-2513118-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2513118-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2513118-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252800-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252800-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011073347-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073347-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252800-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM2 | GRM5 1/4885ALDH1A1 4174/4885NPC1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.